Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?

被引：1
|
作者：
Spieler, Benjamin Oren
Lopes, Gilberto
Dal Pra, Alan
Diwanji, Tejan
Yechieli, Raphael
Freedman, Laura M.
Mihaylov, Ivaylo
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Miami, Parkland, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9579
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
    Liu, Xiaoyu
    Hao, Na
    Yang, Shuangning
    Li, Jieyao
    Wang, Liping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
    Cho, Jun Yeun
    Kim, Junghoon
    Lee, Jong Seok
    Kim, Yu Jung
    Kim, Se Hyun
    Lee, Yeon Joo
    Cho, Young-Jae
    Yoon, Ho Il
    Lee, Jae Ho
    Lee, Choon-Taek
    Park, Jong Sun
    LUNG CANCER, 2018, 125 : 150 - 156
  • [43] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Osamu Nishiyama
    Shigeki Shimizu
    Koji Haratani
    Kosuke Isomoto
    Junko Tanizaki
    Hidetoshi Hayashi
    Ryo Yamazaki
    Takashi Oomori
    Yusaku Nishikawa
    Akiko Sano
    Kazuhiko Nakagawa
    Yuji Tohda
    BMC Pulmonary Medicine, 21
  • [44] Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Pang, Li
    Xie, Mei
    Ma, Xidong
    Huang, Aiben
    Song, Jialin
    Yao, Jie
    Deng, Hui
    Zhang, Duchao
    Zang, Xuelei
    Ren, Fangping
    Gao, Jie
    Wu, Chongchong
    Wang, Yuanyong
    Zhang, Xin
    Bao, Xinyu
    Pan, Lei
    Xue, Xinying
    BMC CANCER, 2023, 23 (01)
  • [45] Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
    Stensgaard, S.
    Thomsen, A.
    Dissing, J. G.
    Knudsen, S. H.
    Meldgaard, P.
    Sorensen, B. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S381 - S381
  • [46] INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
    Yam, A. O.
    Mersiadis, A.
    Gao, B.
    Hui, R.
    Nagrial, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 72
  • [47] Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
    Hou, Xinlei
    Shi, Xueliang
    Luo, Jie
    ONCOLOGY LETTERS, 2022, 24 (01)
  • [48] Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients
    Wang, Shuhong
    Yang, Min
    Chen, Dan
    Liang, Meiling
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (06): : 2483 - 2491
  • [49] Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies
    Yam, Andrew
    Barnet, Megan
    Mersiades, Anthony
    Gao, Bo
    Kao, Steven
    Boyer, Michael
    Hui, Rina
    Nagrial, Adnan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1308 - S1308
  • [50] Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients
    Kamphorst, Alice O.
    Pillai, Rathi N.
    Yang, Shu
    Akondy, Rama
    Koenig, Lydia
    Yu, Ke
    McCausland, Megan
    Sica, Gabriel
    Khuri, Fadlo R.
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Ahmed, Rafi
    CANCER RESEARCH, 2015, 75
12345